ODI Pharma AB receives loan financing of EUR 350,000
ODI Pharma AB (“ODI” or “the Company”) hereby announces that the Company has secured loan financing of EUR 350,000 from an external international party in order to create flexibility in the operations.Loan financing terms and purpose in summary ODI has, as communicated in January 2023, received approval of the Company’s Marketing Authorization Holder (MAH) application from the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products in Poland to distribute and sell its products on the Polish market. The Company thus has the right to distribute and sell its